Market Cap 118.46M
Revenue (ttm) 0.00
Net Income (ttm) -20.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 793,200
Avg Vol 1,514,644
Day's Range N/A - N/A
Shares Out 38.46M
Stochastic %K 50%
Beta 0.06
Analysts Strong Sell
Price Target $7.60

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 500 1556
Address:
4800 Montgomery Lane, Suite 220, Bethesda, United States
SmartOptionsAlert
SmartOptionsAlert Dec. 25 at 1:18 PM
🔎 $GANX Options Scan Update (07:18 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 25 at 9:57 AM
Enter: $GANX Calls Strike Price: $4 Expiry Date: JAN 16 2026 Buy in Price: $0.25 - $0.31 Sell Price: $0.56 Profit : +82% (Turn every $1 into $1.82) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
FinovationF
FinovationF Dec. 25 at 7:30 AM
$GANX Upside depends on translating ambition into measurable cadence, while valuation increasingly tracks execution consistency. Proof points carry more weight than guidance alone.
1 · Reply
wallstreet1929
wallstreet1929 Dec. 25 at 3:51 AM
$GANX I had both Grok and ChatGBT rank 5 stocks I would hold in 2026. Gemini had already ranked GANX as #1, and provided reasons. Surprisingly (to me), both Grok and ChatGBT ranked GANX at #5. Gemini described Grok and ChatGBT as "standard AI models" that were "risk-averse," especially in analyzing biotechs.
1 · Reply
BushCamper
BushCamper Dec. 25 at 12:36 AM
$GANX After some evaluation my opinion is the Warrant Holders at $2.75 and $1.65 were the ones shorting on the December 18th data drop. Their warrants were well in the money with the SP at $4+ in premarket. The December 18th data wasn’t everything that was expected. So by shorting a proportional amount of shares to their warrant holdings. (Only a few million dollars worth). They were able to hedge their unrealized gains on the warrants with a large short. They essentially got to see the data without risk. Once they evaluated that it wasn’t enough to send the share price to the moon, they locked in profit. They now are making more money with the Warrants going back into the money leading up to the KOL event. Perhaps a situation to keep an eye as I predict SP appreciation into the event over the next couple weeks.
3 · Reply
NearEyeOptic
NearEyeOptic Dec. 24 at 11:10 PM
$GANX " robust reduction in cerebrospinal fluid (CSF) levels of glucosylsphingosine (GluSph)"
0 · Reply
zamped1
zamped1 Dec. 24 at 10:31 PM
$GANX Qhat happened to Billymike????? On the board incessantly every day?? Did he cut bait and take a kne??? Was he really a long or????
2 · Reply
microcapspeculator
microcapspeculator Dec. 24 at 9:19 PM
$GANX Nice article. Looking forward to January 6th data. Happy Holidays. GT-02287 boosts enzyme activity in Parkinson’s brain: Trial data Developer Gain Therapeutics to review results in January webinar GT-02287, an oral therapy being developed by Gain Therapeutics, can increase glucocerebrosidase (GCase) enzyme activity in the brains of people with Parkinson’s disease. High levels of GluSph — a sign that the GCase enzyme is not working properly — can promote the buildup of alpha-synuclein, a hallmark of Parkinson’s, and disrupt energy production and other essential processes inside nerve cells. https://parkinsonsnewstoday.com/news/gt-02287-boosts-enzyme-activity-parkinsons-brain-trial-data/
2 · Reply
PaulWalter
PaulWalter Dec. 24 at 8:53 PM
$GANX Happy Christmas everyone.
0 · Reply
whodat2025
whodat2025 Dec. 24 at 8:48 PM
$GANX merry Xmas and happy holiday team GAIN. I’ve thoroughly enjoyed getting to collaborate with a number of you. Should be some exciting times in front of us. Stay safe and enjoy your families.
0 · Reply
Latest News on GANX
Gain Therapeutics to Present at Neuroscience 2025

Oct 30, 2025, 7:00 AM EDT - 2 months ago

Gain Therapeutics to Present at Neuroscience 2025


Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 16, 2025, 7:00 AM EDT - 2 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit


Gain Therapeutics Announces Proposed Public Offering

Jul 15, 2025, 4:36 PM EDT - 5 months ago

Gain Therapeutics Announces Proposed Public Offering


Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 28, 2025, 8:30 AM EDT - 9 months ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025


Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Mar 6, 2025, 7:55 AM EST - 10 months ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025


Gain Therapeutics To Present At Biotech Showcase 2025

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025


Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript


Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO


SmartOptionsAlert
SmartOptionsAlert Dec. 25 at 1:18 PM
🔎 $GANX Options Scan Update (07:18 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 25 at 9:57 AM
Enter: $GANX Calls Strike Price: $4 Expiry Date: JAN 16 2026 Buy in Price: $0.25 - $0.31 Sell Price: $0.56 Profit : +82% (Turn every $1 into $1.82) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
FinovationF
FinovationF Dec. 25 at 7:30 AM
$GANX Upside depends on translating ambition into measurable cadence, while valuation increasingly tracks execution consistency. Proof points carry more weight than guidance alone.
1 · Reply
wallstreet1929
wallstreet1929 Dec. 25 at 3:51 AM
$GANX I had both Grok and ChatGBT rank 5 stocks I would hold in 2026. Gemini had already ranked GANX as #1, and provided reasons. Surprisingly (to me), both Grok and ChatGBT ranked GANX at #5. Gemini described Grok and ChatGBT as "standard AI models" that were "risk-averse," especially in analyzing biotechs.
1 · Reply
BushCamper
BushCamper Dec. 25 at 12:36 AM
$GANX After some evaluation my opinion is the Warrant Holders at $2.75 and $1.65 were the ones shorting on the December 18th data drop. Their warrants were well in the money with the SP at $4+ in premarket. The December 18th data wasn’t everything that was expected. So by shorting a proportional amount of shares to their warrant holdings. (Only a few million dollars worth). They were able to hedge their unrealized gains on the warrants with a large short. They essentially got to see the data without risk. Once they evaluated that it wasn’t enough to send the share price to the moon, they locked in profit. They now are making more money with the Warrants going back into the money leading up to the KOL event. Perhaps a situation to keep an eye as I predict SP appreciation into the event over the next couple weeks.
3 · Reply
NearEyeOptic
NearEyeOptic Dec. 24 at 11:10 PM
$GANX " robust reduction in cerebrospinal fluid (CSF) levels of glucosylsphingosine (GluSph)"
0 · Reply
zamped1
zamped1 Dec. 24 at 10:31 PM
$GANX Qhat happened to Billymike????? On the board incessantly every day?? Did he cut bait and take a kne??? Was he really a long or????
2 · Reply
microcapspeculator
microcapspeculator Dec. 24 at 9:19 PM
$GANX Nice article. Looking forward to January 6th data. Happy Holidays. GT-02287 boosts enzyme activity in Parkinson’s brain: Trial data Developer Gain Therapeutics to review results in January webinar GT-02287, an oral therapy being developed by Gain Therapeutics, can increase glucocerebrosidase (GCase) enzyme activity in the brains of people with Parkinson’s disease. High levels of GluSph — a sign that the GCase enzyme is not working properly — can promote the buildup of alpha-synuclein, a hallmark of Parkinson’s, and disrupt energy production and other essential processes inside nerve cells. https://parkinsonsnewstoday.com/news/gt-02287-boosts-enzyme-activity-parkinsons-brain-trial-data/
2 · Reply
PaulWalter
PaulWalter Dec. 24 at 8:53 PM
$GANX Happy Christmas everyone.
0 · Reply
whodat2025
whodat2025 Dec. 24 at 8:48 PM
$GANX merry Xmas and happy holiday team GAIN. I’ve thoroughly enjoyed getting to collaborate with a number of you. Should be some exciting times in front of us. Stay safe and enjoy your families.
0 · Reply
Random_2wheels
Random_2wheels Dec. 24 at 6:33 PM
$GANX Great price action for a holiday! Non of us pulling out!
0 · Reply
hispeeddev
hispeeddev Dec. 24 at 6:21 PM
$GANX just remember folks, before you go to bed tonight make your Christmas wish. Don't tell anyone or your wish may not come true. Gene told us this is a buy at 10, 15 and 20. He did not tell us what his Christmas wish was for a buy out price.
0 · Reply
mwb1
mwb1 Dec. 24 at 6:02 PM
$GANX Last year on Christmas Eve, we had volume of 111K and closed at $1.59. Today we closed at $3.22 on volume of 773k. We've come a long way, but have much further to go. Wishing everyone a Merry Christmas.
0 · Reply
gatorsgrip
gatorsgrip Dec. 24 at 5:49 PM
$GANX Merry Christmas to all the longs and to the shorts lost in reality--Happy Festivus...
0 · Reply
MQuick
MQuick Dec. 24 at 5:23 PM
$GANX @microcapspeculator @Jwa68 @mwb1 any benefit for BP to announce a deal prior to year end?
1 · Reply
MarkeTimer
MarkeTimer Dec. 24 at 5:23 PM
$GANX A close over $3.30 wouldn't suck
0 · Reply
HahaYouSUCK
HahaYouSUCK Dec. 24 at 5:02 PM
$GANX lol nice drop
0 · Reply
gatorsgrip
gatorsgrip Dec. 24 at 4:58 PM
$GANX Seems like the same playbook as yesterday. Someone shorting the rips, trying to get a red close. Borrow rates up to 158 basis pts. Resolute....
1 · Reply
MQuick
MQuick Dec. 24 at 4:55 PM
$GANX well it seems the algos dont get christmas eve off
0 · Reply
gatorsgrip
gatorsgrip Dec. 24 at 4:35 PM
$GANX Nice green day/volume on a Christmas eve when at this time last week, the proverbial sky was falling. I'd expect this to continue with earnest into the new year.
1 · Reply
Mstngman99
Mstngman99 Dec. 24 at 4:27 PM
0 · Reply
Rustinpeace_
Rustinpeace_ Dec. 24 at 4:26 PM
0 · Reply